Table 1.
Demographic and clinical characteristics of the patients who received prior anti-PD-(L)1 treatment and the entire cohort.
| Prior anti-PD-(L)1 n = 80 | No prior anti-PD-(L)1 n = 11 | Entire cohort N = 91 | |
|---|---|---|---|
| Age (years), median (IQR) | 63 (57–70) | 70 (64–75) | 64 (58–70) |
| Sexa | |||
| Female | 57 (71%) | 7 (64%) | 64 (70%) |
| Male | 23 (29%) | 4 (36%) | 27 (30%) |
| Presence of liver metastasis | 14 (18%) | 3 (27%) | 17 (19%) |
| PD-L1 expression | |||
| <1% | 24 (30%) | 7 (64%) | 31 (34%) |
| 1–49% | 22 (28%) | 1 (9%) | 23 (25%) |
| ≥50% | 25 (31%) | 3 (27%) | 31 (28%) |
| Not available | 9 (11%) | 0 | 9 (10%) |
| Anti-PD-(L)1 as last line of treatment before sotorasib | 51 (64%) | N/A | N/A |
| Type of anti-PD-(L)1 | N/A | N/A | |
| Pembrolizumabb | 58 (73%) | ||
| 200 mg Q3W | 52 (65%) | ||
| 400 mg Q6W | 6 (8%) | ||
| Nivolumab | 11 (14%) | ||
| 240 mg Q2W | 5 (6%) | ||
| 480 mg Q4W | 6 (8%) | ||
| Durvalumab | 9 (11%) | ||
| Atezolizumab | 2 (3%) | ||
| Time on anti-PD-(L)1 (months), median (IQR) | 6.7 (2.9–11.3) | N/A | N/A |
| Time between anti-PD-(L)1 and start sotorasib | N/A | N/A | |
| Median, days (IQR) | 62 (45–258) | ||
| ≤6 weeks | 18 (23%) | ||
| 6–12 weeks | 24 (30%) | ||
| ≥12 weeks | 38 (48%) | ||
| Prior hepatotoxicity during anti-PD-(L)1 | 8 (10%) | N/A | N/A |
| Time on sotorasib (months), median (IQR) | 3.5 (2.2–7.2) | 4.2 (2.7–14.0) | 3.7 (2.6–7.0) |
| Starting dose sotorasibc | |||
| 960 mg | 77 (96%) | 11 (100%) | 88 (97%) |
| 480 mg | 3 (4%) | 0 | 3 (3%) |
a
Self-reported by patient.
b
Monotherapy or in combination with platinum-based chemotherapy.
c
At the treating physician's discretion patients could be started on a lower dose to minimize the risk of toxicities. Percentages may not add up to 100% due to rounding. IQR, interquartile range; PD-(L)1, programmed death (ligand)-1; QxW, every x weeks; N/A, not applicable.